A Phase 1 interventional study of BIIB074 and Valproic Acid in Drug Interaction, sponsored by Biogen. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-04-20.
Sponsored by Biogen · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary objective of this study is to evaluate the effect of multiple doses of the UGT inhibitor valproic acid on the single-dose pharmacokinetics of BIIB074. The secondary objectives of this study are to evaluate the safety and tolerability of BIIB074 when administered alone and when coadministered with the UGT inhibitor valproic acid and to evaluate the effect of the UGT inhibitor valproic acid on the PK of the M13, M14, and M16 metabolites of BIIB074.
Biogen is the lead sponsor of 512 studies on the registry; 25 are open to participants now.
Of its 100 completed or terminated interventional studies of FDA-regulated products, 50 (50%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Key Exclusion Criteria:
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive BIIB074 in tablet form in 150 mg doses. BIIB074 will be taken once daily (QD) on Days 1-16 after an 8-hour fast. Valproic Acid will be given in capsule form in 500 mg doses on prescription (TID) every 8 hours on Days 8-22. The morning dose on Day 16 will be coadministered with BIIB074 following an 8-hour fast.
Drug: BIIB074 · Drug: Valproic Acid
Administered as specified in the treatment arm
Administered as specified in the treatment arm
Also known as: Depakote, Depakene, Stavzor, and Valproic
Maximum Observed Concentration (Cmax) of BIIB074
Time frame: Day 1 through Day 8, Day 16 through Day 23
Area Under the Concentration-Time Curve from Time 0 to Infinity (AUCinf) of BIIB074
Time frame: Day 1 through Day 8, Day 16 through Day 23
Area Under the Concentration-Time Curve from Time Zero to Time of the Last Measurable Concentration (AUClast) of BIIB074
Time frame: Day 1 through Day 8, Day 16 through Day 23
Time to Reach Maximum Observed Concentration (Tmax) for BIIB074
Time frame: Day 1 through Day 8, Day 16 through Day 23
Time of Last Measured Serum Concentration (Tlast) of BIIB074
Time frame: Day 1 through Day 8, Day 16 through Day 23
Elimination Half-Life (T 1/2) of BIIB074
Time frame: Day 1 through Day 8, Day 16 through Day 23
Apparent Clearance (CL/F) of BIIB074
Time frame: Day 1 through Day 8, Day 16 through Day 23
Apparent Volume of Distribution (V/F) of BIIB074
Time frame: Day 1 through Day 8, Day 16 through Day 23
Percentage of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
An AE is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment.
Time frame: Up to Day 32
Number of Participants with Abnormal Change from Baseline of Electrocardiogram (ECG) up to Day 23
Time frame: Day 1, 3, 8, 13, 16, 18, 23
Number of Participants with Abnormal Change from Baseline of Clinical Laboratory Parameters up to Day 23
Time frame: Day 3, 8, 13, 16, 18, 23
Number of Participants with Abnormal Change from Baseline of Vital Signs up to Day 23
Time frame: Day 1, 3, 8, 13, 16, 18, 23
Cmax of BIIB074 Metabolites M13, M14, and M16
Time frame: Day 1 through Day 8, Day 16 through Day 23
AUCinf of BIIB074 Metabolites M13, M14, and M16
Time frame: Day 1 through Day 8, Day 16 through Day 23
AUClast of BIIB074 Metabolites M13, M14, and M16
Time frame: Day 1 through Day 8, Day 16 through Day 23
Tmax of BIIB074 Metabolites M13, M14, and M16
Time frame: Day 1 through Day 8, Day 16 through Day 23
Tlast of BIIB074 Metabolites M13, M14, and M16
Time frame: Day 1 through Day 8, Day 16 through Day 23
T1/2 of BIIB074 Metabolites M13, M14, and M16
Time frame: Day 1 through Day 8, Day 16 through Day 23
Metabolite-to-Parent Ratio in AUC (MRauc) of BIIB074 Metabolites M13, M14, and M16
Time frame: Day 1 through Day 8, Day 16 through Day 23
Number of Participants with Abnormal Change from Baseline in Columbia Suicide Severity Rating (C-SSRS) scale
C-SSRS is a suicidal ideation rating used to evaluate suicidality in children ages 12 and up. It rates an individual's degree of suicidal ideation on a scale, ranging from "wish to be dead" to "active suicidal ideation with specific plan and intent
Time frame: Day 8, 23, and once between Day 29-32
Ran from Sep 2017 to primary completion in Oct 2017, 1 month.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Vixotrigine · Valproic Acid